Southern Research Institute is located in Birmingham, AL. The organization was established in 1945. According to its NTEE Classification (U33) the organization is classified as: Chemistry & Chemical Engineering, under the broad grouping of Science & Technology and related organizations. As of 12/2021, Southern Research Institute employed 491 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Southern Research Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Southern Research Institute generated $85.7m in total revenue. This represents relatively stable growth, over the past 6 years the organization has increased revenue by an average of 3.5% each year. All expenses for the organization totaled $77.1m during the year ending 12/2021. You can explore the organizations financials more deeply in the financial statements section below.
Form
990T
Mission & Program ActivityExcerpts From the 990T Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
TO OFFER RESEARCH & TECHNOLOGY SERVICES TO SUPPORT INDUSTRY AND FEDERAL GOVERNMENT AGENCIES.
Describe the Organization's Program Activity:
DRUG DEVELOPMENT PROVIDES DRUG DISCOVERY AND PRE-CLINICAL DRUG DEVELOPMENT TO PHARMACEUTICAL AND BIOTECHNOLOGY ON AN OUTSOURCED BASIS. SOUTHERN RESEARCH INSTITUTE HAS CAPABILITIES IN ALL PHASES OF THE EARLY-STAGE DRUG DISCOVERY AND DEVELOPMENT PROCESS AND PROVIDES CLIENTS WITH COMPREHENSIVE SERVICES AND SUPPORT TO ASSIST THEM IN STREAMLINING THEIR CUSTOM DRUG DISCOVERY AND DEVELOPMENT PROGRAMS. SOME OF SOUTHERN RESEARCH INSTITUTE'S SIGNIFICANT PRE-CLINICAL RESEARCH ACCOMPLISHMENTS INCLUDE: DEMONSTRATED THE EFFICACY OF COMBINATION CHEMOTHERAPY IN MICE, LEADING THE WAY FOR THE DEVELOPMENT OF THERAPEUTIC APPROACHES WITH IMPROVED CLINICAL OUTCOMES IN CERTAIN CANCERS, PERFORMED PRE-CLINICAL DRUG DEVELOPMENT EVALUATIONS AND ANALYSES ON APPROXIMATELY HALF OF THE FDA-APPROVED CANCER THERAPEUTICS CURRENTLY ON THE MARKET, AND CONTRIBUTED TO THE DEVELOPMENT OF THE FIRST DRUG DELIVERY TECHNOLOGY FOR THE EXTENDED RELEASE OF SYNTHETIC AGENTS THAT PROMOTE THE TREATMENT OF PROSTATE CANCER.
THE ENGINEERING DIVISION DEVELOPS ENGINEERING SOLUTIONS TO COMPLEX PROBLEMS THROUGH CHARACTERIZING THE MECHANICAL, THERMAL, PHYSICAL, AND CHEMICAL PROPERTIES OF ADVANCED MATERIALS. THE ENGINEERING DIVISION IS ALSO DEVELOPING NEW, LOW-COST PROCESSES TO PRODUCE CARBON/CARBON AND POLYMER MATRIX COMPOSITE MATERIALS AND AEROGELS (ULTRA-LIGHT FOAM), AS WELL AS PROCESSING METHODS TO FABRICATE THESE MATERIALS FOR A WIDE VARIETY OF APPLICATIONS FROM AUTOMOTIVE AND RECREATIONAL PRODUCTS TO THE MOST ADVANCED AEROSPACE APPLICATIONS. SOUTHERN RESEARCH INSTITUTE ALSO PROVIDES ENVIRONMENTAL RESEARCH AND SERVICES TO GOVERNMENT, INDUSTRY, AND PRIVATE INSTITUTIONS. THE RESEARCH HAS LED TO THE DEVELOPMENT OF NEW TEST METHODS AND INSTRUMENTS, THE IMPROVEMENT OF PROCESS AND EMISSION CONTROL TECHNOLOGIES, SOLUTIONS TO DAUNTING NEW ENVIRONMENTAL CHALLENGES, AND OTHER IMPORTANT CONTRIBUTIONS TO ENVIRONMENTAL SCIENCES.
DRUG DISCOVERY HAS ACCOMPLISHED INNOVATIVE RESEARCH IN THE AREAS OF CANCER, INFECTIOUS DISEASE, AND NEUROSCIENCE. WITH A FOCUS ON THE DISCOVERY OF NEW, SMALL-MOLECULE THERAPEUTICS AND THE UNDERSTANDING OF HOW THESE MOLECULES WORK, DRUG DISCOVERY CARRIES OUT TRANSLATIONAL SCIENCE DESIGNED TO INVENT SMALL MOLECULES AND ADVANCE THEM FROM THE DESIGN STAGE TO THE CLINIC. GOVERNMENT FUNDING SUPPORTS OUR EFFORTS IN PIONEERING NEW SCIENTIFIC AREAS OF DRUG DISCOVERY. THE DRUG DISCOVERY STAFF PROVIDES EXPERTISE IN MEDICINAL CHEMISTRY, MOLECULAR BIOLOGY, BIOCHEMISTRY, AND HIGH-THROUGHPUT SCREENING TECHNOLOGIES, ALL FOCUSED ON MAKING DISCOVERIES THAT WILL CONTRIBUTE TO IMPROVING HUMAN HEALTH. THE DRUG DISCOVERY TEAM HAS BEEN VERY EFFECTIVE IN ITS EFFORTS AND HAS DISCOVERED MORE THAN 20 DRUGS THAT HAVE ENTERED CLINICAL TRIALS AND SIX DRUGS THAT HAVE BEEN APPROVED BY THE FDA FOR USE IN THE TREATMENT OF CANCER.
SOUTHERN RESEARCH'S STEM EDUCATION OUTREACH PROGRAM IS INVOLVED IN A WIDE VARIETY OF PROGRAMS THAT IMPACT STUDENTS AND TEACHERS IN ALABAMA. THE MISSION OF SR'S STEM PROGRAM IS TO ENHANCE 6TH 12TH GRADE STEM EDUCATION BY DRAWING UPON THE EXPERTISE AND SCHOLARLY CONTRIBUTIONS OF THE SOUTHERN RESEARCH COMMUNITY. WE AIM TO DEFINE AND EXEMPLIFY EFFECTIVE STEM EDUCATION TO MAXIMIZE STUDENTS' READINESS TO EXCEL IN A RAPIDLY CHANGING WORLD. WE ARE WORKING TO ACHIEVE OUR EDUCATION MISSION BY ENGAGING STUDENTS AND TEACHERS IN STEM ACTIVITIES THROUGH SUMMER LEARNING PROGRAMS, FIELD TRIPS, AFTER-SCHOOL PROGRAMING, STEM COMPETITIONS AND SCIENCE FAIRS, INTERNSHIPS, AND PROFESSIONAL DEVELOPMENT WORKSHOPS FOR STEM EDUCATORS. OUR PRIMARY OBJECTIVE IS TO EMBOLDEN STUDENTS WHO POSSESS A PASSION FOR INNOVATION AND DISCOVERY TO PURSUE THEIR INTERESTS AND STRENGTHEN THE STEM COMMUNITY. SOUTHERN RESEARCH IS COMMITTED TO FOSTERING CREATIVITY AND IMPACTING THE FUTURE GENERATION.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Mark Suto Vp, Life Sciences | Officer | 40 | $345,734 |
Michael D Johns VP Engineering | Officer | 40 | $270,300 |
Wendy Brandner Senior Business Development Executive | 40 | $254,571 | |
Ce Augelli-Szafran Interim Vp, Scientific Platform | Officer | 40 | $253,260 |
Fusataka Koide Director, Virology | 40 | $249,518 | |
Timothy Ferguson Distinguished Fellow Engineer | 40 | $244,693 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Materials Research And Design Inc Ee Structural Design And Analysis | 12/30/21 | $639,780 |
University Of Alabama At Birmingham Steam And Contract Services | 12/30/21 | $1,859,148 |
Regions Bank Financial Services | 12/30/21 | $829,769 |
Tiaa Cref Financial Services | 12/30/21 | $3,736,190 |
Flir Commercial Systems Design And Productions Of Thermal Imagin | 12/30/21 | $652,468 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $155,458 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $155,458 |
Total Program Service Revenue | $80,785,233 |
Investment income | $418,953 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $29,100 |
Net Gain/Loss on Asset Sales | $4,257,517 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $85,654,710 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $1,192,246 |
Compensation of current officers, directors, key employees. | $289,716 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $28,150,540 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $11,099,211 |
Payroll taxes | $0 |
Fees for services: Management | $0 |
Fees for services: Legal | $159,189 |
Fees for services: Accounting | $310,224 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $92,505 |
Fees for services: Other | $9,421,810 |
Advertising and promotion | $261,245 |
Office expenses | $8,688,276 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $2,412,107 |
Travel | $418,514 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $327,827 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $5,643,278 |
Insurance | $1,188,440 |
All other expenses | $311,806 |
Total functional expenses | $77,111,881 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $2,218,692 |
Savings and temporary cash investments | $15,201 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $20,639,167 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $920,111 |
Prepaid expenses and deferred charges | $814,499 |
Net Land, buildings, and equipment | $30,344,063 |
Investments—publicly traded securities | $63,878,732 |
Investments—other securities | $593,910 |
Investments—program-related | $0 |
Intangible assets | $2,103,141 |
Other assets | $2,742,520 |
Total assets | $124,270,036 |
Accounts payable and accrued expenses | $6,880,456 |
Grants payable | $0 |
Deferred revenue | $9,710,441 |
Tax-exempt bond liabilities | $13,628,883 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $1,960,536 |
Total liabilities | $32,180,316 |
Net assets without donor restrictions | $0 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $18,818,321 |
Retained earnings, endowment, accumulated income, or other funds | $73,271,399 |
Total liabilities and net assets/fund balances | $124,270,036 |
Over the last fiscal year, Southern Research Institute has awarded $26,400 in support to 4 organizations.
Grant Recipient | Amount |
---|---|
Birmingham, AL PURPOSE: GENERAL SUPPORT | $10,000 |
Birmingham, AL PURPOSE: GENERAL SUPPORT | $6,400 |
Kennesaw, GA PURPOSE: GENERAL SUPPORT | $5,000 |
Birmingham, AL PURPOSE: GENERAL SUPPORT | $5,000 |
Over the last fiscal year, we have identified 3 grants that Southern Research Institute has recieved totaling $232,944.
Awarding Organization | Amount |
---|---|
Michael J Fox Foundation For Parkinsons Research New York, NY PURPOSE: PARKINSON'S RESEARCH | $133,097 |
Louise Maytag Smith Charitable Tr Montgomery, AL PURPOSE: LIFE SCIENCES RESEARCH | $74,847 |
Breast Cancer Research Foundation Of Alabama Birmingham, AL PURPOSE: THE FUNDS ARE USED FOR EXPANDING INNOVATIVE CANCER RESEARCH AND FOR PURCHASING NECESSARY SUPPLIES NEEDED FOR THIS RESEARCH. | $25,000 |
Beg. Balance | $12,226,041 |
Earnings | $1,670,896 |
Admin Expense | $30,937 |
Other Expense | $557,524 |
Ending Balance | $13,308,476 |
Organization Name | Assets | Revenue |
---|---|---|
Mitre Corporation Mclean, VA | $1,037,661,762 | $514,545,047 |
Noblis Inc Reston, VA | $324,675,614 | $469,627,519 |
Logistics Management Institute McLean, VA | $243,065,154 | $422,975,916 |
Institute For Defense Analyses Alexandria, VA | $672,323,901 | $270,097,367 |
Medical Technology Enterprise Consortium Summerville, SC | $73,218,609 | $159,782,022 |
American Type Culture Collection Manassas, VA | $184,874,682 | $176,916,659 |
Mriglobal Kansas City, MO | $133,438,499 | $116,109,484 |
Public Interest Registry Reston, VA | $67,348,678 | $103,286,594 |
Analytic Services Inc Falls Church, VA | $183,098,732 | $88,248,392 |
Southern Research Institute Birmingham, AL | $124,270,036 | $85,654,710 |
International Information System Security Certification Consortium Clearwater, FL | $115,725,304 | $70,448,515 |
Hudson-Alpha Institute For Biotechnology Huntsville, AL | $211,512,056 | $51,805,437 |